AVANIR Pharmaceuticals Invites Investors to Listen to the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals C
29 Marzo 2006 - 11:15PM
Business Wire
AVANIR Pharmaceuticals (AMEX:AVN.R) will be presenting at the CIBC
World Markets Annual Biotechnology & Specialty Pharmaceuticals
Conference on Tuesday, April 4, 2006 at 9:30 a.m. ET in New York.
AVANIR's President and Chief Executive Officer, Eric Brandt, will
be presenting at the investor conference. The presentation will be
available via a live webcast accessible through AVANIR's corporate
website at www.avanir.com. To access the webcast, log on to
AVANIR's site fifteen minutes prior to the presentation to register
and download any necessary audio software. An archive of the
presentation will be available until July 4, 2006. About AVANIR
AVANIR Pharmaceuticals is focused on developing and commercializing
novel therapeutic products for the treatment of chronic diseases.
AVANIR's product candidates address therapeutic markets that
include central nervous system and cardiovascular disorders,
inflammation, and infectious diseases. AVANIR previously announced
positive results in the second of two required Phase III clinical
trials of Neurodex(TM), an investigational new drug for the
treatment of involuntary emotional expression disorder (IEED).
Additionally, AVANIR has initiated a Phase III clinical trial for
Neurodex as a potential treatment in patients with diabetic
neuropathic pain, a second indication for Neurodex. AVANIR has
active collaborations with two international pharmaceutical
companies: Novartis International Pharmaceutical Ltd., for the
treatment of inflammatory disease and AstraZeneca, for the
treatment of cardiovascular disease. The Company's first
commercialized product, "abreva(R)", is marketed in North America
by GlaxoSmithKline Consumer Healthcare and is the leading
over-the-counter product for the treatment of cold sores. Further
information about AVANIR can be found at www.avanir.com. FORWARD
LOOKING STATEMENT Statements in this press release that are not
historical facts, including statements that are preceded by,
followed by, or that include such words as "estimate",
"anticipate", "believe", "plan", or "expect", or similar
statements, are forward-looking statements that are subject to
certain risks and uncertainties that could cause actual results to
differ materially from the future results expressed or implied by
such statements. There can be no assurance that AVANIR's new drug
application for Neurodex(TM) will be accepted for filing by the FDA
within the anticipated time period or at all; that Neurodex will
receive regulatory approval; or that even if such regulatory
approval is received, AVANIR will be able to market Neurodex
successfully. Final review decisions made by the FDA and other
regulatory agencies concerning clinical trial results are often
unpredictable and outside the influence and/or control of the
company. Risks and uncertainties also include the risks set forth
in AVANIR's most recent Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q and from time-to-time in other
publicly available information regarding the Company. Copies of
this information are available from AVANIR upon request. AVANIR
disclaims any intent or obligation to update these forward-looking
statements.
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Avanir Pharmaceuticl (Borsa Americana (AMEX)): 0 articoli recenti
Più AVANIR Pharmaceuticals Articoli Notizie